Last reviewed · How we verify
Insulin Lispro Premix
Insulin Lispro Premix is a Insulin premix Small molecule drug developed by Eli Lilly and Company. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus. Also known as: Humalog Mix25, Humalog Mix50, LY275585.
Insulin lispro premix is a fixed combination of rapid-acting insulin lispro and intermediate-acting insulin isophane that mimics physiologic insulin secretion by providing both mealtime and basal glucose control.
Insulin lispro premix is a fixed combination of rapid-acting insulin lispro and intermediate-acting insulin isophane that mimics physiologic insulin secretion by providing both mealtime and basal glucose control. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Lispro Premix |
|---|---|
| Also known as | Humalog Mix25, Humalog Mix50, LY275585 |
| Sponsor | Eli Lilly and Company |
| Drug class | Insulin premix |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells, promoting glucose uptake and utilization. The premix formulation combines this with isophane (NPH) insulin, which has a longer duration of action, allowing a single injection to cover both postprandial (meal-related) glucose spikes and basal insulin needs throughout the day.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast (PHASE4)
- Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Lispro Premix CI brief — competitive landscape report
- Insulin Lispro Premix updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about Insulin Lispro Premix
What is Insulin Lispro Premix?
How does Insulin Lispro Premix work?
What is Insulin Lispro Premix used for?
Who makes Insulin Lispro Premix?
Is Insulin Lispro Premix also known as anything else?
What drug class is Insulin Lispro Premix in?
What development phase is Insulin Lispro Premix in?
What are the side effects of Insulin Lispro Premix?
What does Insulin Lispro Premix target?
Related
- Drug class: All Insulin premix drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: Eli Lilly and Company — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: Humalog Mix25, Humalog Mix50, LY275585
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing